Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAROTID-STABILISE: Alirocumab in Symptomatic Vulnerable Carotid Plaque
NCT07586540Phase 3Not yet recruiting
- Sponsor
- MENASINO
- Start
- Jul 2027
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of alirocumab in carotid artery stenosis, sponsored by MENASINO. Planned start Jul 2027; status: not yet recruiting.
02
Drugs
alirocumab
03
Conditions
carotid artery stenosis
Beyond the preview
Go deeper on NCT07586540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586540.